Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial

The Lancet Oncology

Volumn 13, Issue 9, 2012, Pages 916-926

  Malmström, Annika ^a   Grønberg, Bjørn Henning ^c   Marosi, Christine ^d   Stupp, Roger ^e   Frappaz, Didier ^f   Schultz, Henrik ^g   Abacioglu, Ufuk ^h   Tavelin, Björn ⁱ   Lhermitte, Benoit ^e   Hegi, Monika E ^e   Rosell, Johan ^b   Henriksson, Roger ^i,j  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Department of Clinical Immunology and Transfusion Medicine   (Sweden)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f CENTRE LÉON BÉRARD   (France)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

ⁱ UMEÅ UNIVERSITY   (Sweden)

^j Regional Cancer Center Stockholm and Gotland   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

AGED; ARTICLE; ASTHENIA; AUSTRIA; BLEEDING; BRAIN HEMORRHAGE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DENMARK; FATIGUE; FEMALE; FEVER; FRANCE; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INFECTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METHYLATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NORWAY; PANCYTOPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SEIZURE; STANDARD RADIOTHERAPY; SWEDEN; SWITZERLAND; THROMBOCYTOPENIA; THROMBOEMBOLISM; TURKEY (REPUBLIC); VOMITING;

AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; EVIDENCE-BASED MEDICINE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84865558322     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70265-6     Document Type: Article

References (29)

1. Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011, 103:714-736.
2. Bergenheim T, Malmstrom A, Bolander H, et al. Registration on regional basis of patients with primary brain tumors. Regional differences disclosed. Lakartidningen 2007, 104:332-338. (in Swedish).
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
4. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
5. Combs SE, Wagner J, Bischof M, et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 2008, 70:987-992.
6. Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 2008, 88:97-103.
7. Sijben AE, McIntyre JB, Roldan GB, et al. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 2008, 89:97-103.
8. Brandes AA, Franceschi E, Tosoni A, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009, 115:3512-3518.
9. Gerstein J, Franz K, Steinbach JP, et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol 2010, 97:382-386.
10. Fiorica F, Berretta M, Colosimo C, et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. Arch Gerontol Geriatr 2010, 51:31-35.
11. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993, 29A:940-942.
12. Chinot OL, Barrie M, Frauger E, et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 2004, 100:2208-2214.
13. Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003, 97:2262-2266.
14. Thomas R, James N, Guerrero D, Ashley S, Gregor A, Brada M Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother Oncol 1994, 33:113-116.
15. Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, Cairncross JG A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1994, 29:835-839.
16. Osoba D, Aaronson NK, Muller M, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 1996, 5:139-150.
17. WHO handbook for reporting results of cancer treatment 1979, WHO, World Health Organization, Geneva.
18. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
19. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010, 20:245-254.
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847.
21. Yan P, Seelentag W, Bachmann A, Bosman FT An agarose matrix facilitates sectioning of tissue microarray blocks. J Histochem Cytochem 2007, 55:21-24.
22. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008, 10:332-337.
23. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007, 356:1527-1535.
24. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004, 22:1583-1588.
25. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012, 13:707-715.
26. Osoba D, Brada M, Yung WK, Prados M Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 2000, 18:1481-1491.
27. Osoba D, Brada M, Yung WK, Prados MD Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 2000, 36:1788-1795.
28. Gallego Perez-Larraya J, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011, 29:3050-3055.
29. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.